333. Hutchinson-Gilford syndrome
7 clinical trials,   8 drugs   (DrugBank: 3 drugs),   4 drug target genes,   6 drug target pathways

Searched query = "Hutchinson-Gilford syndrome", "Hutchinson-Gilford progeria syndrome", "HGPS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03895528
(ClinicalTrials.gov)
January 3, 202027/3/2019Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid LaminopathyA Treatment IND (Investigational New Drug) Protocol for EAP (Expanded Access Program) for the Use of Lonafarnib in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) or Progeroid LaminopathyProgeria;HGPSDrug: LonafarnibEiger BioPharmaceuticalsNULLAvailable12 MonthsN/AAllNULL
2NCT00916747
(ClinicalTrials.gov)
August 20095/6/2009Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaAn Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid LaminopathiesProgeriaDrug: Lonafarnib, Zoledronic Acid, and PravastatinBoston Children's HospitalSchering-Plough;Merck Sharp & Dohme Corp.Enrolling by invitationN/AN/AAll85Phase 2United States
3NCT00879034
(ClinicalTrials.gov)
March 20098/4/2009A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaA Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: Lonafarnib;Drug: Zoledronic Acid;Drug: PravastatinBoston Children's HospitalDana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-PloughCompletedN/AN/AAll5Phase 2United States
4NCT00425607
(ClinicalTrials.gov)
May 200722/1/2007Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaAn Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid LaminopathiesProgeria;Hutchinson-Gilford SyndromeDrug: LonafarnibMonica E. KleinmanSchering-PloughCompleted1 YearN/AAll29Phase 2United States